James Bligh

CIK: 0001990748

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CDT

CONDUIT PHARMACEUTICALS INC.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

CDT
CDT Equity Inc.
Sep 19, 2025
Award(A)
Direct
480K shares-
CDT
CONDUIT PHARMACEUTICALS INC.
Nov 18, 2024
Award(A)
Stock Option (Right to Buy)
Direct
1.9M shares at avg. $0.09-

		Type	Shares	Price		Ownership
Sep 19, 2025	CDT CDT Equity Inc.	Award(A)	480,000	-	-	Direct
Nov 18, 2024	CDT CONDUIT PHARMACEUTICALS INC.	Award(A) Stock Option (Right to Buy)	1,890,000	$0.09	-	Direct

1-2 of 2 transactions

About Bligh James

Bligh James (SEC CIK 0001990748) files insider reports with the SEC as Interim CFO of CONDUIT PHARMACEUTICALS INC. (CDT).

Signal8 holds 2 ownership filings by Bligh James, all Form 4s, filed between Nov 20, 2024 and Sep 19, 2025. Those filings report 2 transactions, from Nov 18, 2024 to Sep 19, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Bligh James's filings is in NAPLES, FL.

Recent filings by Bligh James

Sep 19, 2025: Grant or award of CDT shares (Form 4, code A).
Nov 18, 2024: Grant or award of CDT derivative securities (Form 4, code A).

Other insiders filing for CONDUIT PHARMACEUTICALS INC. (CDT)

Regan Andrew, Chief Executive Officer
Manoira Corp, 10% Owner
Taylor Mark Andrew, 10% Owner
Farley Chele Chiavacci, Director
Fry Simon Jeremy, Director
Lewis-Hall Freda C, Director

How to read Form 4 transaction codes